论文部分内容阅读
中美史克公司是一间世界领先以科技为基础的制药企业。一直以来,都在致力于抗感冒药品新技术和新配方的研究和发展,中美史克公司在新康克生产设备、厂房改造以及相应配套工程上的投资,达到一亿四千五百万元人民币。正是这一从未间断的研发程序,使史克能在PPA事件后很快就推出了不含PPA的新药。 新康泰克的新配方,已得到国家药监局的验证通过。新改进的配方,应用安全,疗效确切,质量可靠,使用方便,符合作为非处方药的标准。
Sino-US Shi Ke company is a world-leading science and technology-based pharmaceutical companies. All along, we are devoted to the research and development of anti-cold medicine new technologies and new formulations. Sino-US Schick invested 145 million in Xin Kangke’s production facilities, factory buildings and corresponding supporting projects Yuan Renminbi. It is this never-ending development program that enabled Schneckel to launch a new PPA-free drug soon after the PPA incident. New Contac’s new formula has been verified by the SFDA. The new improved formula, application safety, efficacy, reliable, easy to use, in line with standards as a non-prescription drugs.